Introduction
The myeloid leukemias including acute myelogenous leukemia (AML) and chronic myelogenous leukemia (CML) are neoplastic disorders characterized by the aberrant proliferation and differentiation of myeloid precursor cells. AML is a remarkably heterogenous disease and is associated with multiple different types of genetic mutations.
These mutations are generally of two functional types including those which (1) interfere with the differentiation of myeloid precursors and (2) dysregulate the proliferation and viability of these myeloid precursors (1) . For example AML-specific chromosome translocations and mutations involving the RARα (2), AML-1(3) and C/EBPα (4) genes interfere with the differentiation of myeloid precursors while mutations involving tyrosine kinase receptors such as c-kit (5) and flt-3 (6) dysregulate their proliferation and viability. Other specific signal transduction pathways that are aberrantly activated in AML include those involving ras/raf/MAPKinase (7), Stat3 (8) , SRC -related kinases (9) and PI3 kinase/Akt (10) . Similarly in CML the oncogenic bcr-abl tyrosine kinase that is generated by the Ph chromosome is associated with the activation of multiple downstream signal transduction pathways including Stat5 (11) , MAPK (12) , PI3 Kinase (13) and SRC-family kinases (14) . The most widely studied of these Ca ++ regulated enzymes is CaMKII, which consists of four homologous but distinct genes (CaMKIIα, β, γ, δ). One of the critical functional characteristics of CaMKII is its distinct holoenzyme structure consisting of 12 identical subunits (16) . Activation of individual subunits of this dodecameric holoenzyme by Ca ++ /calmodulin leads to the phosphorylation of adjacent enzyme subunits at threonine286 (for the α isoform) or at threonine287 (for the β, γ, and δ isoforms) (17) .
This CaMKII autophosphorylation leads to increased enzymatic activity and markedly diminishes the requirement for Ca ++ /calmodulin binding to maintain enzymatic activity (18) . Thus the autophosphorylated CaMKII is autonomous and relatively independent of Ca ++ concentration and Ca ++ /calmodulin regulation.
CaMKII comprises approximately 1-2% of total brain protein, and previous studies have identified an important role of this enzyme in regulating neuronal cell development and activity (19) . Other studies using pharmacological inhibitors of the CaMKs have indicated a role for CaMKII in regulating the cell cycle progression of cultured NIH 3T3
fibroblasts (20, 21) . In contrast studies determining the role of CaMKII in regulating hematopoiesis have been relatively limited. In T lymphocytes CaMKII is involved in regulating cytokine expression (22) and TCR-triggered cell proliferation (23) as well as the generation of memory T cells (24) . In previous studies we have observed that
CaMKIIγ is the CaMKII isoform that is preferentially expressed in myeloid cells, and this enzyme inhibits the retinoic acid induced differentiation of myeloid leukemia cell lines by phosphorylating and inhibiting the transcriptional activity of the retinoic acid receptor (RARα) (25) . In these previous efforts we observed that CaMKII inhibitors enhance the differentiation of certain myeloid leukemia cell lines, but this effect was only noted in leukemias that were responsive to retinoic acid (25) . In the present study we extend these studies beyond the retinoic acid responsive myeloid leukemias and describe a Figure 1A ). To further investigate the role of CaMKIIγ in the pathogenesis of human leukemia the present study focuses on the myeloid leukemias, and we observe that the activated, autophosphorylated CaMKIIγ is also present at varying levels in the majority (11/16) of primary patient AML samples Oncogenic bcr-abl regulates CaMKIIγ activation. In contrast to its lack of response to ATRA, the K562 cell line, derived from a patient with CML, undergoes proliferative arrest following exposure to imatinib (gleevec), which is a potent inhibitor of the tyrosine kinase activity of the bcr-abl oncogene.
We observed that this imatinib -induced proliferation arrest is accompanied by a rapid, marked decrease in autophosphorylated CaMKIIγ, while there was no significant change in the total levels of CaMKIIγ following this imatinib exposure ( Figure 3A ).
The marked downregulation of CaMKII activation (autophosphorylation) by the bcrabl inhibitor, imatinib observed in K562 cells suggests that the activation of CaMKIIγ in these CML cells requires bcr-abl activity. To confirm this we utilized the TonB210.1 cell line, which is a Baf3 -derived line whose proliferation/viability is dependent upon either IL-3 alone or the tet-regulated expression of bcr-abl (tet-on) (37) . We observe in the TonB210.1 cells that the decreased bcr-abl expression associated with tet withdrawal is also accompanied by a marked and relatively rapid (within 4 hours) reduction in the levels of activated (autophosphorylated) CaMKII, while total CaMKIIγ levels remain unchanged ( Figure 3B ). (Fig. 4A, i) . In contrast STO609, a potent small molecule inhibitor of CaMKinase Kinase (CaMKK)(40) did not significantly inhibit K562 proliferation nor did KN92, an inactive structural analog of KN62 (Fig. 4A, ii) . The KN93 induced inhibition of K562 cell proliferation was accompanied by a reduction in the levels of the activated (autophosphorylated) CaMKIIγ (Fig. 5A, row 1 ). KN93 did not affect K562 viability, and no effect on the morphologic differentiation of these cells was observed. A similar KN93-mediated inhibition of cell proliferation without any significant effect on cell viability or morphologic differentiation was also noted in other cultured myeloid leukemia cell lines including KG-1, KCL22, THP1, and Kasumi (Fig. 4B ).
To further assess the role of CaMKIIγ in regulating myeloid leukemia cell We also observe that the KN93 induced downregulation of CaMKII activation is associated with a marked reduction in GSK3β Ser9 phosphorylation (Fig. 5A, row 6 ).
This is of particular interest since GSK3β, a serine/threonine kinase, phosphorylates and promotes the degradation of β-catenin, a key component of the Wnt signaling pathway, which is frequently activated in myeloid leukemia (43, 44) . Since phosphorylation of
GSK3β at Ser9 inhibits the activity of this enzyme (45), we would predict that the KN93 induced reduction in GSK3β Ser9 phosphorylation would lead to enhanced GSK3β enzyme activity associated with enhanced degradation of β-catenin. Indeed a marked reduction in the expression of β-catenin is observed in the KN93 treated K562 cells ( (Fig. 6A , ii). Our observation that the CaMKII inhibitor KN93 induces a decrease in Stat3 Ser727 phosphorylation (Fig. 5A, row 11) suggests that Stat3 may be a direct substrate of CaMKIIγ in myeloid leukemia cells. Consistent with this we observe that 9/11 of the primary AML samples that exhibit CaMKIIγ activation (Fig. 1B ) also exhibit Stat3 Ser727 phosphorylation, while none of the five primary AML samples that were negative for CaMKIIγ activation exhibit Stat3 Ser 727 phosphorylation (Fig. 6A, ii) . In addition we observe in the TonB210 cells that the tet-induced bcr-abl induction is associated with a marked increase in Stat3 Ser727 phosphorylation without any change in total Stat3 levels (Fig. 6B,   compare lanes 1 vs 2) . Moreover, this enhanced Stat3 Ser727 phosphorylation is blocked by KN62 or KN93 (Fig. 6B, lanes 3, 4) indicating that a CaM kinase is involved in this bcr-abl induced Stat3 Ser727 phosphorylation. We also observe that cucurbitacin I, a small molecule Stat3 inhibitor, will, as expected, inhibit Stat3 responsive reporter activity, and this reporter activity is also inhibited by KN93 in a dose dependent manner (Fig. 6C ). These latter observations indicate a functional interaction between Stat3 and CaMKII in myeloid leukemia cells.
To further assess the CaMKIIγ / Stat3 interaction we observed that in K562 cells Stat3 co-immunoprecipitates with CaMKIIγ (Fig. 6D, i) . Moreover, CaMKIIγ phosphorylates Stat3 at Ser727 both in vitro (Fig. 6D , ii) and in vivo (Fig. 6D, iii) . Together these observations suggest that Stat3 is likely a direct substrate of CaMKIIγ in myeloid leukemia cells and that the KN93 induced inhibition of K562 cell proliferation (Fig. 4A) may be mediated, at least in part, through its inhibition of Stat3 Ser727 phosphorylation.
Discussion
The CaM kinases (CaMKs) are major targets of Ca ++ regulated physiological events, and the role of a particular CaMK, (i.e. CaMKII), in regulating both neuronal and cardiac muscle cell development and activity has been well established. Our present study Closely related to the question of how CaMKIIγ is activated in myeloid leukemia cells is how this enzyme becomes inactivated (dephosphorylated) during terminal myeloid differentiation/growth arrest (Fig. 2) . Indeed we observe a prominent decrease in Moreover, the localization of CaMKII to the mammalian midbody also suggests a role for this enzyme in regulating cytokinesis (52) . We have previously observed that CaMKIIγ directly phosphorylates and inhibits the transcriptional activity of RARα, which is an important regulator of the terminal differentiation of certain myeloid leukemia cells (25) .
Our present study indicates that Stat3, which exhibits oncogenic activity (49) , is directly phosphorylated by CaMKIIγ, and this phosphorylation enhances Stat3 transcriptional activity (Fig. 6 ). We also observe that CaMKIIγ directly or indirectly promotes the inhibitory phosphorylation of GSK3β, an enzyme which normally downregulates the expression of cell growth/proliferation factors including β-catenin, c-myc and cyclinD1 (Fig. 5B) . Thus CaMKII activity appears to orchestrate a complex, interacting network of molecular events that are involved in regulating the proliferation of myeloid leukemia cells.
Our observation that CaMKIIγ is an important regulator of multiple phosphoprotein signaling networks regulating myeloid leukemia cell proliferation suggests that targeting this enzyme might be of therapeutic benefit in human myeloid leukemia. Indeed we reproducibly observe an inhibition of myeloid leukemia cell proliferation triggered by 
